Koji Kakihata

Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey†

Tomoo Shiozawa, Jun-ichi Tadokoro, T Fujiki et al. · Japanese Journal of Clinical Oncology · 2013 · 38 citations · Full text

Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

Kiyoshi Takasuna, Y Kasai, Yutaka Kitano et al. · Folia Pharmacologica Japonica · 1995 · 33 citations · Full text

Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor

Munehiro Tomikawa, Shin-ichiro Ashida, Koji Kakihata et al. · Thrombosis Research · 1978 · 32 citations

Thrombopoiesis, Thrombosis, Blood Platelet +9

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports

Noritoshi Yoshii, Tadamichi Suzuki, Masaki Nagashima et al. · Anti-Cancer Drugs · 2011 · 25 citations

Antifibrotic Therapy, Death Rate, Inflammatory Lung Disease +11

Initial lesions in chickens infected with JM strain of Marek's disease virus.

Y. Fujimoto, K. Okada, Koji Kakihata et al. · PubMed · 1974 · 21 citations · Full text

Poultry Disease, Pathogenesis, Viral Pathogenesis +9